Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 13-Aug 4:05 PM ET)
Why Investors Are Watching These Healthcare Movers
Globe Newswire (Thu, 6-Aug 12:31 PM ET)
Globe Newswire (Thu, 6-Aug 8:00 AM ET)
Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
Globe Newswire (Wed, 15-Jul 7:00 AM ET)
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
Globe Newswire (Tue, 14-Jul 4:03 PM ET)
Presenting on Emerging Growth Conference 94 Day 1 on July 15; Register to live stream
Globe Newswire (Tue, 14-Jul 7:00 AM ET)
Market Chameleon (Wed, 8-Jul 6:32 AM ET)
Globe Newswire (Tue, 7-Jul 7:35 AM ET)
Business Wire (Thu, 2-Jul 8:00 AM ET)
Globe Newswire (Thu, 2-Jul 8:00 AM ET)
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Vivani Medical trades on the NASDAQ stock market under the symbol VANI.
As of August 31, 2026, VANI stock price declined to $1.39 with 204,763 million shares trading.
VANI has a beta of 2.07, meaning it tends to be more sensitive to market movements. VANI has a correlation of 0.19 to the broad based SPY ETF.
VANI has a market cap of $125.38 million. This is considered a Micro Cap stock.
In the last 3 years, VANI traded as high as $7.80 and as low as $.84.
The top ETF exchange traded funds that VANI belongs to (by Net Assets): VTI, VXF, IWC.
VANI has underperformed the market in the last year with a return of +17.8%, while SPY returned +19.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VANI shares. However, VANI has outperformed the market in the last 3 month and 2 week periods, returning +7.8% and -0.7%, while SPY returned +1.9% and -1.2%, respectively. This indicates VANI has been having a stronger performance recently.
VANI support price is $1.36 and resistance is $1.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VANI shares will trade within this expected range on the day.
